Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 443651 in Healthy Male Volunteers
NCT02706925Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in cystic fibrosis (CF) and asthma comparing BI 443651 with Placebo (2 arms). Primary endpoint: Percentage of Subjects With Drug-related Adverse Events (AEs) up to 216 hours. Started Mar 2016; status: completed.
02
Drugs
BI-443651
03
Conditions
cystic fibrosis (CF)asthma
Beyond the preview
Go deeper on NCT02706925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706925.